Cargando…

Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors

Specifically targeted drug delivery systems with low immunogenicity and toxicity are deemed to increase efficacy of cancer chemotherapy. Acridine Orange (AO) is an acidophilic dye with a strong tumoricidal action following excitation with a light source at 466 nm. However, to date the clinical use o...

Descripción completa

Detalles Bibliográficos
Autores principales: Iessi, Elisabetta, Logozzi, Mariantonia, Lugini, Luana, Azzarito, Tommaso, Federici, Cristina, Spugnini, Enrico Pierluigi, Mizzoni, Davide, Di Raimo, Rossella, Angelini, Daniela F., Battistini, Luca, Cecchetti, Serena, Fais, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010124/
https://www.ncbi.nlm.nih.gov/pubmed/28262028
http://dx.doi.org/10.1080/14756366.2017.1292263
_version_ 1783333529800671232
author Iessi, Elisabetta
Logozzi, Mariantonia
Lugini, Luana
Azzarito, Tommaso
Federici, Cristina
Spugnini, Enrico Pierluigi
Mizzoni, Davide
Di Raimo, Rossella
Angelini, Daniela F.
Battistini, Luca
Cecchetti, Serena
Fais, Stefano
author_facet Iessi, Elisabetta
Logozzi, Mariantonia
Lugini, Luana
Azzarito, Tommaso
Federici, Cristina
Spugnini, Enrico Pierluigi
Mizzoni, Davide
Di Raimo, Rossella
Angelini, Daniela F.
Battistini, Luca
Cecchetti, Serena
Fais, Stefano
author_sort Iessi, Elisabetta
collection PubMed
description Specifically targeted drug delivery systems with low immunogenicity and toxicity are deemed to increase efficacy of cancer chemotherapy. Acridine Orange (AO) is an acidophilic dye with a strong tumoricidal action following excitation with a light source at 466 nm. However, to date the clinical use of AO is limited by the potential side effects elicited by systemic administration. The endogenous nanocarrier exosomes have been recently introduced as a natural delivery system for therapeutic molecules. In this article, we show the outcome of the administration to human melanoma cells of AO charged Exosomes (Exo-AO), in both monolayer and spheroid models. The results showed an extended drug delivery time of Exo-AO to melanoma cells as compared to the free AO, improving the cytotoxicity of AO. This study shows that Exo-AO have a great potential for a real exploitation as a new theranostic approach against tumors based on AO delivered through the exosomes.
format Online
Article
Text
id pubmed-6010124
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-60101242018-07-11 Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors Iessi, Elisabetta Logozzi, Mariantonia Lugini, Luana Azzarito, Tommaso Federici, Cristina Spugnini, Enrico Pierluigi Mizzoni, Davide Di Raimo, Rossella Angelini, Daniela F. Battistini, Luca Cecchetti, Serena Fais, Stefano J Enzyme Inhib Med Chem Research Article Specifically targeted drug delivery systems with low immunogenicity and toxicity are deemed to increase efficacy of cancer chemotherapy. Acridine Orange (AO) is an acidophilic dye with a strong tumoricidal action following excitation with a light source at 466 nm. However, to date the clinical use of AO is limited by the potential side effects elicited by systemic administration. The endogenous nanocarrier exosomes have been recently introduced as a natural delivery system for therapeutic molecules. In this article, we show the outcome of the administration to human melanoma cells of AO charged Exosomes (Exo-AO), in both monolayer and spheroid models. The results showed an extended drug delivery time of Exo-AO to melanoma cells as compared to the free AO, improving the cytotoxicity of AO. This study shows that Exo-AO have a great potential for a real exploitation as a new theranostic approach against tumors based on AO delivered through the exosomes. Taylor & Francis 2017-03-06 /pmc/articles/PMC6010124/ /pubmed/28262028 http://dx.doi.org/10.1080/14756366.2017.1292263 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Iessi, Elisabetta
Logozzi, Mariantonia
Lugini, Luana
Azzarito, Tommaso
Federici, Cristina
Spugnini, Enrico Pierluigi
Mizzoni, Davide
Di Raimo, Rossella
Angelini, Daniela F.
Battistini, Luca
Cecchetti, Serena
Fais, Stefano
Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
title Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
title_full Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
title_fullStr Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
title_full_unstemmed Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
title_short Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors
title_sort acridine orange/exosomes increase the delivery and the effectiveness of acridine orange in human melanoma cells: a new prototype for theranostics of tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010124/
https://www.ncbi.nlm.nih.gov/pubmed/28262028
http://dx.doi.org/10.1080/14756366.2017.1292263
work_keys_str_mv AT iessielisabetta acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT logozzimariantonia acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT luginiluana acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT azzaritotommaso acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT federicicristina acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT spugninienricopierluigi acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT mizzonidavide acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT diraimorossella acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT angelinidanielaf acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT battistiniluca acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT cecchettiserena acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors
AT faisstefano acridineorangeexosomesincreasethedeliveryandtheeffectivenessofacridineorangeinhumanmelanomacellsanewprototypefortheranosticsoftumors